---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000112"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:30:44.666794+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M

## Summary
- Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.
- Net loss $92.6M ($0.10/share) vs $134.6M in Q2 2024; operating loss narrowed.
- Cash $153.7M at June 30; $80M equity financing closed July 2025 with potential $96M warrant proceeds.
- UK MHRA approved ANKTIVA for BCG-unresponsive NMIBC; FDA refused to file sBLA for papillary-only NMIBC, company re-evaluating.
- ANKTIVA unit volume grew 246% in 1H 2025 vs 2H 2024 since J-code approval.

## SEC filing metadata
- accession: 0001326110-25-000112
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/0001326110-25-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/ibrx-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000112
- JSON: https://secwatch.observer/filing/0001326110-25-000112.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.